Amantadine for dyskinesia in patients affected by severe Parkinson's disease

Citation
C. Paci et al., Amantadine for dyskinesia in patients affected by severe Parkinson's disease, NEUROL SCI, 22(1), 2001, pp. 75-76
Citations number
8
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Neurology
Journal title
NEUROLOGICAL SCIENCES
ISSN journal
1590-1874 → ACNP
Volume
22
Issue
1
Year of publication
2001
Pages
75 - 76
Database
ISI
SICI code
1590-1874(200102)22:1<75:AFDIPA>2.0.ZU;2-K
Abstract
20 patients (12 men and 8 women, mean age 65 years) affected by severe Park inson's disease (PD) with peak-dose and/or diphasic dyskinesias or painful dyskinesia were treated with amantadine (300 mg/day) as adjunctive therapy to current levodopa, carbidopa and dopaminoagonist. UPDRS (Unified Parkinso n's disease rating scale), dyskinesias rating scale (DRS) and IGA (investig ator global assessment) scale were used to evaluate the severity of PD symp toms during follow-up. After 15 days with amantadine treatment all patients improved with an average 38% reduction in dyskinesias (p<0.001). After 2-8 months, amantadine was withdrawn in all patients. After amantadine withdra wal, 2 patients experienced severe hyperthermia (39<degrees> C and 40 degre es C). No difference was found between end of treatment dyskinesia scores a nd final withdrawal scores (p<0.5). In the two patients with hyperthermia a mantadine was reintroduced; after four days hyperthermia subsided and amant adine was finally tapered over 15 days without further adverse reactions.